Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival.
about
The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinomaHow admissions to various medical specialty divisions determines the outcome of patients with hepatocellular carcinoma: results from a retrospective study in a large hospital of northwest ChinaGABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma.Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.Loss of 11βHSD1 enhances glycolysis, facilitates intrahepatic metastasis, and indicates poor prognosis in hepatocellular carcinomaNestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance.Conditional disease-free survival after liver transplantation for hepatocellular carcinoma: A two-center experience.Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients.Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.Liver resection for early hepatocellular cancer: Comparison of centers in 3 different countriesImmune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.Expression and clinical significance of PcG-associated protein RYBP in hepatocellular carcinoma.Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection.Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.Genetic susceptibility of eight nonsynonymous polymorphisms in HLA-DRB1 gene to hepatocellular carcinoma in Han Chinese.Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk.Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors.Clinical significance of CMTM4 expression in hepatocellular carcinoma.The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice.Exosomal miRNAs in hepatocellular carcinoma development and clinical responses.Hepa1-6-FLuc cell line with the stable expression of firefly luciferase retains its primary properties with promising bioluminescence imaging ability.
P2860
Q28066407-9C9D6A9B-472A-4940-92E7-2B12A25F6C23Q33597474-4887C7B6-469D-4298-AC2A-997F6254EF6FQ33733761-F7A90E9D-B7EC-4D0A-831C-EB38A5222B28Q36290421-4A839D50-874C-468E-A570-320F7DD533A2Q36739034-F92C9F3A-A1FE-415D-ACC1-99ECDFA570C9Q37093999-17338502-ECF6-4EBD-AE84-2139D98D99FDQ37165028-14C50578-78A9-4098-A010-60CCD723E1D8Q37251634-11CBF560-339D-4EA2-8E7C-9E6A1C0025BFQ37295612-E27683B3-2300-4E1D-95E3-30E256137999Q37317414-00E7B5EE-0820-4CBC-99BC-48DDF0880A83Q37399648-F43079ED-7F3A-4C3D-9247-E26C9F74F378Q37552210-DC7E2496-EF55-4BA7-802A-9D15EB377AA3Q37594051-47BF5EB8-8635-49AF-A3CF-132290440A17Q38966147-B5AAEA4C-94E3-4B04-9525-471C772E5F2BQ40185369-AA021A01-1A83-4926-BACB-9E4DD5AC68C6Q40460745-CE584666-BCE5-468A-BF40-1E8E44E477D5Q40786667-811B77D7-8D11-43D8-9AFC-C36F9AC1E233Q41472938-65C4A128-83F5-47C5-937A-EA367598DAFEQ42283216-F8599579-4CF9-49B1-B452-57F317197168Q45067272-FB514A11-98A0-4A8A-A2F6-2513873F08BFQ47142549-6852C5A2-CDFC-4F7A-8D5B-6AFA9D001494Q52593381-35737EC1-11E5-4326-B2CE-8B773FAF8ED9Q55253520-04B12D5F-1C3E-4401-A22B-AFCD3E9C1C7D
P2860
Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Hepatocellular carcinoma in a ...... option and improving survival.
@ast
Hepatocellular carcinoma in a ...... option and improving survival.
@en
type
label
Hepatocellular carcinoma in a ...... option and improving survival.
@ast
Hepatocellular carcinoma in a ...... option and improving survival.
@en
prefLabel
Hepatocellular carcinoma in a ...... option and improving survival.
@ast
Hepatocellular carcinoma in a ...... option and improving survival.
@en
P2093
P2860
P356
P1433
P1476
Hepatocellular carcinoma in a ...... option and improving survival.
@en
P2093
Cuiling Yang
Qianqian Zhu
Qunying Han
Xiaoyan Zeng
Zhengwen Liu
Zhihua Zhou
P2860
P304
P356
10.18632/ONCOTARGET.2913
P407
P577
2015-02-01T00:00:00Z